Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From&#xa0;a Sub-Study of the FOLL12 Trial

Gastrointestinal Cancer

Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation

Eur J Cancer

Michiel Zeeuw J, Wesdorp NJ, Ali M, Bakker AJJ, Voigt KR, Starmans MPA, Roor J, Kemna R, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, de Wilt JHW, Verpalen IM, Stoker J, Grunhagen DJ, Swijnenburg RJ, Punt CJA, Huiskens J, Verhoef C, Kazemier G

doi: 10.1016/j.ejca.2024.114185

Lymphoma

Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial

Lancet Haematol

Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM

doi: 10.1016/S2352-3026(25)00034-1

Central Nervous System Tumors

Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial

Neuro Oncol

Mynarek M, Rossius A, Guiard A, Ottensmeier H, von Hoff K, Obrecht-Sturm D, Bußenius L, Friedrich C, von Bueren AO, Gerber NU, Traunwieser T, Kortmann RD, Warmuth-Metz M, Bison B, Thomale UW, Krauss J, Pietsch T, Clifford SC, Pfister SM, Sturm D, Sahm F, Tischler T, Rutkowski S

doi: 10.1093/neuonc/noae092

CHICAGO 2025

Genitourinary Cancer

ENZA-p: PSMA tumor volume predicts survival benefit from adding Lu-PSMA-617 to enzalutamide in high-volume, high-risk mCRPC

Multiple Myeloma (MM)

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

Blood

Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL

doi: 10.1182/blood.2024024965

Central Nervous System Tumors

Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ

Neuro Oncol

Zeyen T, Böhm L, Paech D, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Schneider-Rothhaar JL, Steinbach JP, Hau P, Kowalski T, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Gkika E, Vatter H, Radbruch A, Herrlinger U, Weller J, Schaub C

doi: 10.1093/neuonc/noae205

Lung, Respiratory and Thoracic Cancer

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons

J Thorac Oncol

Hoffmann H, Nicholson AG, Detterbeck FC, Tsao MS, Ostrowski M, Rami-Porta R, Borczuk A, Marino M, Travis WD, Van Schil PE, Edwards J, Members of the R-Subcommittee, and Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards

doi: 10.1016/j.jtho.2024.12.007

Lung, Respiratory and Thoracic Cancer

Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter study

Lung Cancer

Megyesfalvi E, Ghimessy A, Bauer J, Pipek O, Saghi K, Gellert A, Fillinger J, Okumus O, Teglas V, Ganofszky E, Bogos K, Renyi-Vamos F, Megyesfalvi Z, Aigner C, Hegedus B, Dome B, Moser B

doi: 10.1016/j.lungcan.2025.108111

Gastrointestinal Cancer

Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer

Eur J Cancer

Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller CA, Kahl C, Seipelt G, Kullmann F, Heinrich K, Holch JW, Alig A, Jung A, Modest DP, Heinemann V

doi: 10.1016/j.ejca.2025.115399

Oncology · Hematology

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

Related content